Conventional Synthetic Disease-modifying Drugs Remain the Mainstay of Therapy for Rheumatoid Arthritis in India

Simple item page
dc.contributor.authorDhir, Ven_US
dc.contributor.authorChiu, SMen_US
dc.contributor.authorGupta, Ren_US
dc.contributor.authorPhillip, SSen_US
dc.contributor.authorShenoy, Pen_US
dc.contributor.authorTaksande, Ben_US
dc.contributor.authorRawal, Den_US
dc.contributor.authorKumar, Ken_US
dc.contributor.authorSingh, Gen_US
dc.contributor.authorKumar, Sen_US
dc.contributor.authorDhuria, Sen_US
dc.contributor.authorManovihar, Aen_US
dc.contributor.authorBhagat, Aen_US
dc.contributor.authorSoni, Cen_US
dc.contributor.authorJain, Sen_US
dc.contributor.authorShobha, V.en_US
dc.date.accessioned2025-05-12T09:38:10Z
dc.date.available2025-05-12T09:38:10Z
dc.date.issued2024-12
dc.description.abstractBackground: There are limited data on the real-world utilization of disease-modifying antirheumatic drugs (DMARDs) in Indian patients with rheumatoid arthritis (RA). Methods: This was a cross-sectional study of a multicentric observational cohort of RA patients across rheumatology clinics at six centers across India. Patients who met the American College of Rheumatology (ACR) 2010 criteria for RA were included. The demographics, disease-related parameters, and current therapy in terms of DMARDs were analyzed using a structured paper or electronic case record form. Results: This study included 4,061 patients with RA across six centers in India. A majority were female (female-to-male ratio, 6:1), and their mean [standard deviation (SD)] age at the time of enrollment was 51 (12.2) years. Rheumatoid factor and/or anti-CCP were positive in 79 and 77%, respectively. Data on DMARDs were available for 3,550 RA patients. Conventional synthetic DMARDs alone were being used in 3,289 (93%), targeted synthetic DMARDs in 203 (6%), and biological DMARDs in 67 (2%). A total of at least 18 separate types or combinations of DMARDs were being prescribed, with the most common being a combination of methotrexate and hydroxychloroquine (22%), methotrexate monotherapy (17%), and a combination of methotrexate and leflunomide (16%). Overall, the most common DMARD prescribed (as monotherapy or in combination) was methotrexate (86%), followed by hydroxychloroquine (52%) and leflunomide (37%). Conclusion: Cs-DMARDs remain the mainstay in the treatment of Indian patients with RA in this study, with the majority being treated with methotrexate alone or in combination with other DMARDs.en_US
dc.identifier.affiliationsDepartment of Internal Medicine (Division of Rheumatology), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarhen_US
dc.identifier.affiliationsDepartment of Internal Medicine (Division of Rheumatology), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarhen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Medanta Institute of Education and Research (MIER), Gurugram, Haryanaen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, St John’s Medical College and Hospital (SJMCH), Bengaluru, Karnatakaen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Centre of Arthritis and Rheumatism Excellence (CARE), Cochin, Keralaen_US
dc.identifier.affiliationsDepartment of Medicine, Mahatma Gandhi Institute of Medial Sciences (MGIMS), Wardha, Maharashtraen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Kusum Dhirajlalen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Medanta Institute of Education and Research (MIER), Gurugram, Haryanaen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Medanta Institute of Education and Research (MIER), Gurugram, Haryanaen_US
dc.identifier.affiliationsDepartment of Internal Medicine (Division of Rheumatology), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarhen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Medanta Institute of Education and Research (MIER), Gurugram, Haryanaen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Centre of Arthritis and Rheumatism Excellence (CARE), Cochin, Keralaen_US
dc.identifier.affiliationsDepartment of Medicine, Mahatma Gandhi Institute of Medial Sciences (MGIMS), Wardha, Maharashtraen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, Kusum Dhirajlal Hospital (KD), Ahmedabad, Gujarat, Indiaen_US
dc.identifier.affiliationsDepartment of Internal Medicine (Division of Rheumatology), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarhen_US
dc.identifier.affiliationsDepartment of Clinical Immunology and Rheumatology, St John’s Medical Collegeen_US
dc.identifier.citationDhir V, Chiu SM, Gupta R, Phillip SS, Shenoy P, Taksande B, Rawal D, Kumar K, Singh G, Kumar S, Dhuria S, Manovihar A, Bhagat A, Soni C, Jain S, Shobha V.. Conventional Synthetic Disease-modifying Drugs Remain the Mainstay of Therapy for Rheumatoid Arthritis in India. Journal of the Association of Physicians of India. 2024 Dec; 72(12): 30-33en_US
dc.identifier.issn0004-5772
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/247351
dc.languageenen_US
dc.publisherJournal of Indian Medical Associationen_US
dc.relation.issuenumber12en_US
dc.relation.volume72en_US
dc.source.urihttps://doi.org/10.59556/japi.72.0756en_US
dc.titleConventional Synthetic Disease-modifying Drugs Remain the Mainstay of Therapy for Rheumatoid Arthritis in Indiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
japi2024v72n12p30.pdf
Size:
4.93 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of the Association of Physicians of India